3 completed, 1 terminated. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Bacterial Pneumonia: new trials by email Literature Review of Bacterial Pneumonia trials Research Report on Bacterial Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cx611-0204 SEPCELL Study Cx611, Placebo - Bacterial Pneumonia | Phase 1 / Phase 2 | Completed | Tigenix S.A.U. | 84 | 2017-01-30 | 2022-04-06 |
| Clinical Trials to Reduce the Risk of Antimicrobial Resistance IV meropenem, I.V. Meropenem, Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h - Bacterial Pneumonia | Phase 2 | Terminated | University of Florida | 43 | 2010-09-01 | 2017-09-29 |
| An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia doripenem - Pneumonia, Bacterial Pneumonia | Phase 2 | Completed | PriCara, Unit of Ortho-McNeil, Inc. | 185 | 2007-08-01 | 2013-09-25 |
| Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036) MK0826, ertapenem sodium /Duration of Treatment: 14 Days, Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days - Urinary Tract Infections, Bacterial Pneumonia | Phase 2 | Completed | Merck Sharp & Dohme LLC | 400 | 2002-01-01 | 2017-02-17 |
Pneumonia, Bacterial (4) · Bacterial Infections (1) · Cross Infection (1) · Pneumonia (1) · Pneumonia, Ventilator-Associated (1) · Pseudomonas Infections (1) · Soft Tissue Infections (1) · Urinary Tract Infections (1)
Bacterial Infections and Mycoses (4) · Infections (4) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Respiratory Tract Infections (4) · Bacterial Infections (3) · Pneumonia (3) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gram-Negative Bacterial Infections (1) · Healthcare-Associated Pneumonia (1) · Iatrogenic Disease (1) · Male Urogenital Diseases (1) · Pathologic Processes (1)
Doripenem (1) · Duration of Therapy (1) · Ertapenem (1) · Linezolid (1) · Meropenem (1) · Tobramycin (1) · Vancomycin (1)
Merck Sharp & Dohme LLC (1) · PriCara, Unit of Ortho-McNeil, Inc. (1) · Tigenix S.A.U. (1) · University of Florida (1)
France (3) · Spain (2) · United States (2) · Argentina (1) · Belgium (1) · Canada (1) · Chile (1) · Croatia (1) · Germany (1) · India (1) · Italy (1) · Lithuania (1) · Norway (1) · Russia (1) · Ukraine (1)
PMID 29038277, PMID 33238991, PMID 37918129
2015 (1)